FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line
Executive Summary
FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products
You may also be interested in...
Lorqess' Slight Efficacy, Potential Safety Issues Leave Arena On The Hot Seat At Advisory Panel
FDA seeks input on the "slim margin" of efficacy and the adequacy of safety data for Arena's obesity drug.
Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner
Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board
Orexigen Empatic That Results For Second Obesity Drug Will Help Lure Partner
Given the potential to cause birth defects, Orexigen's obesity drug Empatic is probably not suited for the masses. Still, executives say the promising combo pill could complement the company's better known obesity agent Contrave and help bring a partner on board